COMMUNIQUÉS West-GlobeNewswire

STERIS To Invest $600 Million to Build a Formulated Chemistries Manufacturing and Distribution Center of Excellence in North Carolina
05/08/2026
• This Formulated Chemistries Center of Excellence will support sterilization and disinfection for the global Healthcare and Pharmaceutical industries • This strategic manufacturing investment is the largest in STERIS’s [...]
IAOMT Supports HHS Directive to Phase Out Mercury Dental Fillings in Medicaid
05/08/2026
CHAMPIONS GATE, Fla., Aug. 05, 2026 (GLOBE NEWSWIRE) -- The International Academy of Oral Medicine and Toxicology (IAOMT) strongly endorses a historic directive from the U.S. Department of Health and Human Services (HHS [...]
BiomX Acquires 10% Stake in Motomea, Inventor of Advanced Electric Motor Technologies for Drone and Autonomous Systems
05/08/2026
Agreement includes an exclusive drone distribution license and an option to acquire a controlling interest in Motomea NETANYA, Israel, Aug. 05, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “ [...]
Verano Announces Strong Second Quarter 2026 Financial Results Highlighted by $218 Million in Revenue
05/08/2026
Company delivers third consecutive quarter of revenue gains and improved cash flow from operations driven by organic growth CHICAGO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO [...]
Shopify Delivers Big: 30%+ Growth Across GMV, Revenue, Gross Profit, and Free Cash Flow
05/08/2026
Internet, Everywhere, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Shopify (NASDAQ, TSX: SHOP) announced today financial results for the quarter ended June 30, 2026. Shopify achieved 34% revenue growth (33% in constant currency) [...]
Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy
05/08/2026
RMAT designation granted based on recent interim clinical data from ongoing Phase I/II clinical trial evaluating LX2020 for PKP2-ACM LX2020 now holds RMAT, Orphan Drug and Fast Track designations by the FDA NEW YORK, [...]
Telix to Host R&D Day in New York City on September 22, 2026
05/08/2026
MELBOURNE, Australia and INDIANAPOLIS, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that it will host a Research and Development (R&D) Day on Tuesday [...]
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
05/08/2026
Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026 KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 [...]
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
05/08/2026
– Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe – – PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 – – Topline data from [...]
BioCryst Reports Second Quarter 2026 Financial Results
05/08/2026
— Total net revenue of $218.3 million and ORLADEYO ® net revenue of $158.2 million — — Operating profit of $98.5 million and Non-GAAP operating profit of $113.2 million — — Maintained Full Year 2026 ORLADEYO revenue [...]
Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights
05/08/2026
Achieved $57.5 million in RYTELO ® (imetelstat) net product revenue in Q2 2026, an increase of 11% compared to Q1 2026 Reiterated 2026 RYTELO net product revenue and total operating expenses expected to be in the ranges [...]
Adneuris Therapeutics Grants Exclusive License to Maruishi Pharmaceutical to Advance Cebranopadol in Japan and South Korea
05/08/2026
Agreement Grants Maruishi Rights for the Development and Commercialization of Cebranopadol for Pain in Japan and South Korea, Marking Adneuris' Second Ex-U.S. Licensing Transaction Under the Terms of the Agreement, [...]
Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026
05/08/2026
Company to host conference call to discuss financial results and provide a corporate update on August 12, 2026 at 4:30 p.m. ET SCOTTSDALE, Ariz., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey [...]
Intelligent Bio Solutions Completes Usability Study Supporting FDA 510(k) Submission
05/08/2026
Study confirms the system can be effectively administered by operators with no specialist background NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a [...]
Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program
05/08/2026
Purchasing $500,000 within First 30 days Since Program Commencement MELBOURNE, Australia, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical [...]
Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG
05/08/2026
Proteomedix Co-Founder and Proclarix® Co-Developer Returns to Company’s Board; Thomas Meier, PhD Re-Elected as Chairman at Annual General Meeting CINCINNATI, Ohio , Aug. 05, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. ( [...]
Vivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device Technology
05/08/2026
Continuation Patent Secures Broader, Design Independent Claims, Building on the Company's 2024 Foundational Patent for Its Vibrational Oral Appliance Platform LITTLETON, Colo., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Vivos [...]
SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome
05/08/2026
TEL AVIV, Israel, Aug. 05, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company [...]
Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
05/08/2026
GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will [...]

Pages